Q1 2025 Acarix AB Earnings Call Transcript
Key Points
- Acarix AB (ACIXF) reported a 46% increase in systems delivered in the US compared to Q1 2024.
- Patch sales surged by 104% in the US, indicating strong adoption of their subscription model.
- The company achieved a 30% increase in top-line revenue, showcasing robust financial performance.
- Acarix AB (ACIXF) won the 2025 Digital Innovation Award, enhancing its reputation in the medical device industry.
- The partnership with Geomed is expected to expand opportunities within the Department of Defense and Veteran Affairs in the US.
- A strategic sale led to a 10-point drop in gross margin, impacting profitability.
- Reimbursement challenges remain, with fixed reimbursement timelines largely outside the company's control.
- Operating expenses were reduced by 6%, but the company still faces a net loss of 14.1%.
- The transition to CPT1 reimbursement is dependent on external approvals, creating uncertainty.
- The company faces challenges in increasing awareness and understanding of its technology in the market.
Hello and welcome to the AAI Q1 2025 earnings call.
Thank you for joining. We're going to get into a lot of dialogue today surrounding what we did in Q1, but most pertinently, we'll start off with all the macroeconomy and all the changes that are going on regarding the geopolitical situations and rhetoric, as well as a lot of these tariffs and macroeconomic environment surrounding logistics and most pertinently supply chains. There's many things that will be continually changing and evolving with the new administration in the US, but we, we're want to make sure that our shareholders are understanding that we are very committed to understanding exactly how things are procuring as best we possibly can because they seem to change on a day to day basis. However, we're having minimal impact in regard to how we function as an organization because most everything we do is coming out of Sweden and Denmark. Where we're seeing a decent tariff, per se of 10%. So it won't have a dramatic impact, but it will have a small impact on our margin as we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
